Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions.
Platelet-derived chemokines, such as regulated on activation, normal T expressed and secreted (RANTES; CC chemokine ligand 5), platelet factor 4 [PF4; CXC chemokine ligand 4 (CXCL4)], and epithelial neutrophil-activating protein 78 (ENA-78; CXCL5), or precursors, such as beta-thromboglobulin, which can be processed to neutrophil-activating protein-2 (NAP-2; CXCL7), may play an important role in monocyte recruitment during atherogenesis. Platelets can deposit chemokines on inflamed endothelium; however, little is known about differential or additive effects of platelet chemokines on monocyte arrest. Here, we demonstrate that preincubation of activated human microvascular endothelial cells (HMVECs) with RANTES, PF4, or NAP-2 but not ENA-78 dose-dependently increased surface immobilization and subsequent monocyte arrest in flow. RANTES was the most potent and efficient arrest chemokine. Pretreatment of HMVECs with beta-thromboglobulin enhanced monocyte arrest in the presence of cathepsin G generating NAP-2. Combined pretreatment of HMVECs with RANTES and PF4 at suboptimal concentrations synergistically increased arrest, and preincubation with chondroitinase ABC abrogated RANTES- and PF4-induced monocyte arrest. This was associated with reduced expression of chondroitin sulfate, RANTES, and PF4 on the HMVEC surface. Perfusion of HMVECs with platelets known to deposit RANTES and PF4 on the endothelial surface enhanced monocyte arrest, which was inhibited by Met-RANTES, chondroitinase, or a blocking antibody to PF4 but not to ENA-78. The relevance of platelet-derived chemokines was confirmed in adhesion assays with activated whole blood, where Met-RANTES and to a lesser extent, antibodies to PF4 and NAP-2 inhibited arrest of CD14-positive monocytes. Thus, multiple platelet-derived chemokines and processable precursors, which can be presented by specific endothelial proteoglycans, may contribute and cooperate differentially to induce monocyte recruitment.
Baltus
Thomas
T
Department of Molecular Cardiovascular Research, Universitätsklinikum Aachen, Pauwelstrasse 30, 52074 Aachen, Germany.
von Hundelshausen
Philipp
P
Mause
Sebastian F
SF
Buhre
Wolfgang
W
Rossaint
Rolf
R
Weber
Christian
C
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001161:Arteriosclerosis / Q000378:metabolism / Q000473:pathology; D001792:Blood Platelets / Q000502:physiology*; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D002460:Cell Line; D018925:Chemokines / Q000378:metabolism* / Q000494:pharmacology; D019765:Chondroitin ABC Lyase / Q000494:pharmacology; D004357:Drug Synergism; D004730:Endothelium, Vascular / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D036904:Leukocyte Rolling / Q000187:drug effects / Q000502:physiology*; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D008262:Macrophage Activation / Q000187:drug effects / Q000502:physiology; D009000:Monocytes / Q000502:physiology*
D000911:Antibodies, Monoclonal; D018925:Chemokines; D018950:Lipopolysaccharide Receptors; D019765:Chondroitin ABC Lyase